Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PDO Max is a private U.S. medical aesthetics and medical device company focused on polydioxanone (PDO)-based products for non-surgical aesthetic procedures. The company manufactures and distributes FDA-cleared PDO threads in cannula for soft tissue approximation and cosmetic lifting, and it complements those products with practitioner training, business development support, and related aesthetic tools. Its product portfolio includes multiple PDO thread formats, the topical skin booster PDO AfterGlo, the LúmEnvy skin brightening booster, and the Glowpin exfoliation and serum-delivery device. PDO Max primarily serves medspas, aesthetic clinics, and other practitioner offices rather than operating a traditional therapeutic drug-development pipeline. The business appears to be commercially active and privately held, with headquarters in Liverpool, New York.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PDO Max.